Birgitta Versluijs

159 Discussion TABLE 1. Overview of publications on predictors for Allo-LS in children after HCT Author Study population Primary endpoint, identified Predictor Remarks Abugideiri (14) 2016 N=129, 12 (1-21) yr Allo-HCT with TBI IPS : 23.3% TBI (cGy/min) OR 4.94 (1.83-13.35), p=0.002 Duncan (13) 2008 N=216, 9.8 yr BOS: 8.3% aGVHD, p=0.001 cGVHD, p< 0.001 Drug reaction, p< 0.001 Univariate t-test Early viral infection: p=0.15 Gassas (16) 2015 N=39, 8.3 (1-17.2) yr BOS: 15.4% Serum KL-6 pre HCT p<0.05 Serum KL-6 + 1 month p<0.04 Serum KL-6 + 3 months p<0.12 Univariate t-test Gassas (17) 2016 N=39, 8.3 (1-17.2) yr BOS: 15.4% Neutrophil count + 3 months p=0.03 Neutrophil count + 6 months p=0.03 Univariate t-test Madanat (12) 2014 N=51, 11.2 (6.2-19) yr Allo-HCT with TBI IEM excluded Pulmonary dysfunction (clinical or ↓ PFT): 59% Abnormal baseline PFT HR 4.82, (1.02-22.84) p= 0.05 aGVHD HR 4.31,(1.47-12.63), p= 0.008 cGVHD HR 10.2 (1.47-12.63), p=0.002 Univariate Nagasawa (11) 2017 N=67, 6.5 (0.6-22.7) yr only malignancies BOS: 13.4% cGVHD, HR 11.3,(1.77-72.70,p=0.01) RIC: no BOS Small numbers Nishio (10) 2009 N=97, 6.6 (0.4-18) yr BOS/IPS: 10.3% HR-malignancy (no CR) HR 5.42(1.36-21.7), p=0.017 extensive cGVHD HR 11.7 (2.40-57.1), p=0.002 Table continues on next page 9